Available Treatment Options for Later Lines of Therapy in Patients With RRMM

Opinion
Video

Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.

Related Videos
Related Content